17,261 trials
Inflammation · Pain · Cataract
Primary: Proportion of Subjects With Clearing of Anterior Inflammation — 18; 18; 13 Participants
Glabellar Frown Lines
Primary: The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year — 148 Participants
Glabellar Frown Lines
Primary: The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year — 235 Participants
Highly Drug-resistant Focal Epilepsy
Primary: 75 % Responder Rate During the 2-week Inpatient Period — 11.1; 30.8 percentage of participants — p==0.0679
Pulmonary Hypertension
Primary: Changes in RV Function — 7.56 percentage
Pulmonary Arterial Hypertension
Primary: Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil — 8170; 8390; 15200; 4550…
Metastatic Castration-Resistant Prostate Cancer
Primary: Number of Participants With Adverse Events (AEs) — 60; 56; 58; 16 Participants
Cannabis Dependence
Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars
Influenza
Primary: Number of Seroconverted Subjects in Terms of H5N1 Hemagglutination Inhibition (HI) Antibodies Against A/Turkey/Turkey/1/2005 H5N1 Virus Strain — 33; 21; 29; 83…
HIV-1 Infection · Pf Subclinical Parasitemia
Primary: Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance — 0.23; 0.27; 0.77; 0.73 Proportion of participants — p=1.00
Infant, Newborn
Primary: Number of Transfusions During Hospitalization — 1.2; 1.2; 2.4 number of transfusions
Leukemia · Lymphoma · Myeloma
Primary: Maximum Tolerated Dose — 6800 mmol-min/L
Depressive Disorder
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases — -16.8 Score on a scale
Smoking Cessation
Primary: Exhaled Carbon Monoxide (CO) — 10.88; 21.63 Parts p/million
Non-Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose — 200 milligrams PO daily